Study of Axitinib in Patients With Recurred or Metastatic Adenoid Cystic Carcinoma
NCT02859012
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
60
Enrollment
OTHER
Sponsor class
Conditions
Recurrent ACC, metastaticACC, Unreaectable ACC
Interventions
DRUG:
Axitinib
OTHER:
Observation
Sponsor
Seoul National University Hospital